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Abstract	
Magnetic	nanomaterials	show	significant	promise	as	contrast	agents	for	magnetic	resonance	
imaging	 (MRI).	 We	 have	 developed	 a	 new	 highly	 efficient	 one-step	 procedure	 for	 the	
synthesis	 of	 magnetically-functionalised	 hollow	 carbon	 nanofibres,	 where	 (i)	 the	 carbon	
nanofibres	act	as	both	a	template	and	a	support	for	the	nucleation	and	growth	of	magnetite	
nanoparticles	 and	 (ii)	 the	 structural	 (size,	 dispersity	 and	 morphology)	 and	 functional	
(magnetisation	 and	 coercivity)	 properties	 of	 the	 magnetic	 nanoparticles	 formed	 on	
nanofibres	 are	 strictly	 controlled	 by	 the	 mass	 ratio	 of	 the	 magnetite	 precursor	 to	 the	
nanofibres	and	the	solvent	employed	during	synthesis.	We	have	shown	that	our	magnetite-
nanofibre	materials	are	effectively	solubilised	in	water	resulting	in	a	stable	suspension	that	
has	been	employed	as	a	“negative”	MRI	contrast	agent	with	an	excellent	transverse	relaxivity	
(r2)	 of	 (268	 ±	 13)	 mM/s,	 surpassing	 current	 commercial	 materials	 and	 state-of-the-art	
magnetic	nanoscale	platforms	in	performance	for	MRI	contrast	at	high	magnetic	fields.	The	
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preparation	 and	 evaluation	 of	 this	 unique	 hybrid	 nanomaterial	 represents	 a	 critical	 step	
towards	the	realisation	of	a	highly	efficient	“smart”	MRI	theranostic	agent	–	a	material	that	
allows	 for	 the	 combined	 diagnosis	 (with	 MRI),	 treatment	 (with	 magnetic	 targeting)	 and	
follow-up	of	a	disease	(with	MRI)	–	currently	in	high	demand	for	various	clinical	applications,	
including	personalised	nanomedicine.	
Keywords:	 nanoparticle,	 nanofibre,	 carbon	 nanotube,	 magnetism,	 magnetic	 resonance	
imaging.	
	
1. Introduction	
Hollow	 one-dimensional	 carbon	 nanostructures,	 such	 as	 carbon	 nanotubes	 (CNTs)	 and	
graphitised	nanofibres	(GNFs),	are	chemically	stable	and	mechanically	robust	and	have	been	
demonstrated	as	effective	containers	 for	 functional	molecules	and	nanoparticles.1-5	Whilst	
much	of	the	current	literature	has	focussed	on	the	applications	of	narrow	CNT	as	containers,	
comparatively	 little	 attention	 has	 been	 paid	 to	 GNFs.	 These	 unique	 hybrid	 carbon	
nanostructures	 comprise	an	atomically-smooth	multi-walled	nanotube	exterior	and	a	 cup-
stacked	 interior	which	gives	rise	to	 internal	graphitic	protrusions,	approximately	3.5	nm	in	
height	and	spaced	at	8-15	nm	intervals	along	the	nanofibre	growth	axis,	where	localised	van	
der	Waals	 forces	 are	maximised	 and	molecules	 and	 nanoparticles	 become	 spontaneously	
immobilised	(Figure	1).6-8	
	
	
Figure	 1.	 (a)	 Schematic	 representation	 and	 (b	 and	 c)	 transmission	 electron	 microscope	 (TEM)	
micrographs	highlighting	the	unique	structure	of	graphitised	nanofibres.	The	step-edge	arrangement,	
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denoted	by	the	small	black	arrows	in	(a)	and	the	white	arrows	in	(b	and	c),	provides	an	area	for	both	
molecules	and	nanoparticles	species	to	be	selectively	deposited.	
	
Unlike	 CNTs,	which	 require	 opening	 and	have	 an	 internal	 diameter	 of	 a	 few	nanometres,	
graphitised	 nanofibres	 are	 always	 open	 and	 have	 comparatively	 large	 accessible	 internal	
volumes,	often	more	than	50	nm	in	diameter,	allowing	for	the	rapid,	uninhibited	diffusion	of	
molecules	 and	 nanoparticles	 into	 the	 nanofibres.	 These	 distinguishing	 properties	 of	 GNFs	
make	 them	 superior	 to	CNT	and	 thus	 ideal	 vessels	 for	magnetic	 resonance	 imaging	 (MRI)	
contrast	materials,	such	as	magnetite	nanoparticles	(Fe3O4NP).	Magnetite	composites	have	
shown	significant	promise	for	MRI	methods	due	to	their	excellent	magnetic	characteristics,	
such	as	high	magnetic	saturation;9-11	however,	the	magnetic	properties	of	Fe3O4	are	highly	
dependent	on	the	size,	shape,	crystallinity	and	purity	of	magnetite	nanoparticles	and	their	
distribution	on	a	given	substrate.12,13	The	current	challenge	for	magnetite-based	MRI	contrast	
agents	is	to	engineer	Fe3O4	nanostructures	to	maximise	the	rate	of	transverse	relaxation	(R2)	
whilst	maintaining	a	low	concentration	of	magnetite	in	the	system.	
In	this	comparative	study,	we	appraise	the	structural	and	magnetic	properties	of	a	series	of	
magnetite	 nanoparticle/graphitised	 nanofibre	 composites	 (Fe3O4NP/GNF)	 prepared	 by	
simple	one-step	procedures	 involving	readily	accessible	reagents.	Despite	the	fact	that	the	
formation	of	Fe3O4NP	on	CNTs	has	been	extensively	studied	previously;14-27	surprisingly,	little	
investigation	has	been	performed	on	the	formation	of	magnetite	on	and	in	GNFs	to	date.28-31	
Herein,	we	demonstrate	that	GNFs	serve	as	effective	templates	for	the	in-situ	formation	of	
Fe3O4	 nanoparticles.	We	 show	 that	 reaction	 conditions,	 such	 as	 the	 ratio	 of	 GNF	 to	 iron	
precursor	 and	 the	 solvent	 system	 employed,	 have	 a	 significant	 effect	 on	 the	 size	 and	
morphology	of	Fe3O4	in	the	afforded	GNF	hybrids.	Moreover,	we	observe	that	materials	with	
larger,	 sparsely	 distributed,	 magnetite	 nanoparticles	 on	 GNF	 showed	 the	 best	 magnetic	
characteristics	for	MRI	and	thus	the	greatest	potential	for	dual	functionality	theranostics.	
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2. Experimental	
2.1	 General	Experimental	
Graphitised	nanofibres	 (PR19	Pyrograf	Products,	produced	by	chemical	vapour	deposition,	
mean	length	~5	microns,	mean	inner	and	outer	diameters	are	~50	and	~120	nm	respectively)	
were	purchased	from	Applied	Science,	USA.	All	other	reagents	and	solvents	were	purchased	
from	Sigma-Aldrich,	UK	and	used	without	further	purification.	Water	was	purified	(>	18.0	MΩ	
cm)	using	a	Barnstead	NANOpure	II	system.	High	resolution	transmission	electron	microscopy	
(HRTEM)	was	performed	using	a	JEOL	2100F	transmission	electron	microscope	(field	emission	
electron	gun	source,	information	limit	0.19	nm).	Statistical	analysis	of	nanoparticle	diameter	
(dNP)	was	conducted	using	GatanDigitalMicrograph	software	(N	>	200).	Energy	dispersive	X-
ray	(EDX)	analysis	was	performed	using	an	Oxford	Instruments	INCA	560	X-ray	microanalysis	
system.	TEM/EDX	specimens	were	prepared	by	casting	several	drops	of	methanolic	solutions	
onto	copper-grid-	or	nickel-grid-mounted	“holey”	carbon	films	and	drying	under	a	stream	of	
nitrogen.	Thermogravimetric	analysis	was	determined	using	a	TA	Instrument	equipped	with	
a	 SDT	 Q600	 Analyser	 under	 flowing	 air	 at	 a	 rate	 of	 10	 °C	 min-1	 up	 to	 800	 °C.	 Raman	
spectroscopy	was	 conducted	 using	 a	Horiba–Jobin–YvonLabRAM	HR	 spectrometer,	with	 a	
laser	wavelength	of	532	nm	operating	at	a	power	of	ca.	4	mW	and	a	600	lines	mm-1	grating.	
The	detector	was	a	Synapse	CCD	detector.	Spectra	were	collected	by	averaging	8	acquisitions	
of	60	s	duration.	The	Raman	shift	was	calibrated	using	the	Raleigh	peak	and	the	520.7	cm-1	
silicon	line	from	an	Si(100)	reference	sample.	Measurement	of	the	magnetic	properties	was	
performed	 using	 PPMS-9	 (Physical	 Property	 Measurement	 System,	 EverCool	 II,	 Quantum	
Design)	 in	magnetic	 fields	 up	 to	 9	 T.	 XRD	measurements	were	 carried	out	 using	 a	 Rigaku	
Ultima	IV	X-ray	diffractometer	in	the	Bregg-Brentano	recording	geometry	with	CoKα	radiation	
with	a	graphite	monochromator	on	the	diffracted	beam.	A	Fisherbrand	Accuspin	centrifuge	
was	used	at	6080xg	during	purification	of	the	composite	materials.	
	
2.2	 Preparation	of	Fe3O4NP/GNF	
The	 preparation	 of	 Fe3O4NP/GNF	 was	 achieved	 through	 modification	 of	 the	 procedure	
outlined	by	Chen	et	al.32	GNFs	(25	mg)	were	heated	at	400	oC	for	1	h	to	remove	any	residual	
moisture	from	the	internal	channel.	To	this	was	added	a	solution	of	iron(III)	acetylacetonate	
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(25	mg)	in	deionised	water	(6	mL)	and	the	suspension	sonicated	at	room	temperature	for	2	h.	
The	solvent	was	removed	in	vacuo	and	the	resulting	solid	heated	from	room	temperature	to	
140	oC	at	a	rate	of	2.5	oC	min-1	and	then	held	at	140	oC	for	8	h	in	air.	The	solid	was	subsequently	
further	heated	to	350	oC	at	a	rate	of	2	oC	min-1	under	a	continuous	flow	of	argon	and	held	at	
350	oC	 for	an	additional	3	h.	Other	materials	 reported	 in	 this	work	with	differing	ratios	of	
Fe(acac)3	to	GNF	and	solvent	(Table	1)	were	prepared	in	a	similar	fashion.	
	
2.3	 Biological	applications	
2.3.1	Dispersion	of	Fe3O4NP/GNF	for	biological	applications	
To	Fe3O4NP/GNF-1:2w	(5	mg)	was	added	an	aqueous	solution	of	Pluronic	F-127	(10	mL,	2	%	
v/v)	and	the	mixture	sonicated	for	2	h	at	room	temperature.	After	sonication,	the	dispersion	
was	centrifuged	(6,080xg,	20	min).	Following	centrifugation,	the	supernatant	and	precipitate	
were	 separated	 by	 decantation.	 The	 supernatant	 was	 discarded	 and	 the	 precipitate	 re-
dispersed	in	the	same	volume	of	deionised	water	and	centrifuged	again.	This	procedure	was	
repeated	three	times	to	yield	a	stable	dispersion	of	Fe3O4/GNF:Pluronic	in	deionised	water.	
The	 percentage	 of	 Pluronic	 F-127	 in	 the	 final	 Fe3O4/GNF	 composite	 was	 determined	 by	
thermogravimetric	analysis	of	the	solid	prior	to	the	final	re-dispersion	in	water	and	found	to	
be	3.6	%.	
Five	10	mL	vials	of	Fe3O4NP/GNF-1:2w:Pluronic	F-127	were	prepared	by	dilution	of	the	stock	
solution	to	five		different	concentrations	for	the	use	in	the	MRI	experiments.	
	
2.3.2	MRI	experiments		
MRI	characterisation	was	performed	using	a	9.4	T	Avance	III	micro-imaging	system	(Bruker,	
Germany).	 A	 30	mm	micro-imaging	 1H	 coil	 was	 used	 in	 all	 experiments.	 Standard	MSME	
(Multi-Slice	Multi-Echo)	imaging	protocol	was	used	for	simultaneous	spatial	mapping	of	either	
longitudinal	 (T1)	 or	 transverse	 (T2)	 time	 constants	 of	 water	 protons	 from	 five	 different	
aqueous	dispersions	of	Fe3O4NP/GNF-1:2w:Pluronic	F-127	containing	0.0024561,	0.0064311,	
0.0128622,	0.0184211	and	0.0385866	mM	of	Fe	ion.	T1	time	constants	were	measured	using	
saturation	recovery	method	with	15	pre-pulses	at	time	to	echo	(TE)	of	9.7	ms.	At	least	five	
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recycle	delays	were	used	to	ensure	full	characterization	of	the	mono-exponential	longitudinal	
recovery.	T2	time	constants	were	measured	using	TEs	of	15,	50	and	100	ms	and	a	recycle	delay	
of	3000	ms.	A	0.1	ms	bipolar	pulse	was	used	for	excitation	and	1	ms	Gaussian	pulse	was	used	
for	slice	selective	re-focusing.	Data	from	central	5	mm	axial	slices	were	collected	into	128x128	
matrices	with	isotropic	field	of	view	(FOV)	of	30	mm2,	resulting	in	raw	spatial	resolution	of	
0.234	mm2.	 Data	 were	 zero	 filled	 to	 256x256	 before	 image	 reconstruction.	 Images	 were	
reconstructed	 using	 Prospa	 3.1	 (Magritek,	 New	 Zealand).	 T1	 and	 T2	 data	 analysis	 was	
performed	using	IgorPro	6.1	(Wavemetrics,	USA).	T1	and	T2	time	constants	were	determined	
in	 each	 phantom	 using	 pixel	 by	 pixel	 linear	 fitting	 after	 transforming	 the	 data	 into	 semi-
logarithmic	 scale	 as	 mono-exponential	 proton	 relaxation	 behaviour	 was	 assumed.	
Subsequent	 determination	 of	 the	 averaged	 T1	 and	 T2	 values	 and	 their	 variances	 was	
performed	using	Gaussian	multi-peak	build-in	subroutine.	
	
3. Results	and	discussion	
The	thermal	decomposition	of	 iron(III)	acetylacetonate	(Fe(acac)3)	was	chosen	as	the	 ideal	
method	 for	 the	preparation	of	Fe3O4	nanoparticles	owing	 to	 its	 synthetic	ease	and	use	of	
cheap,	widely	accessible	reagents.	As	Fe(acac)3	had	to	be	both	deposited	on	and	encapsulated	
in	GNFs	to	provide	the	precursor	for	the	nanoparticles,	it	was,	therefore,	essential	to	control	
the	physical	properties	of	the	solvent	to	ensure	optimum	deposition.	We,	thus,	explored	the	
use	of	both	water	and	a	mixture	of	water	and	ethanol	for	the	effective	solvation	of	Fe(acac)3.	
In	 a	 typical	 experiment,	 the	 metal	 complex	 was	 dissolved	 in	 water	 or	 a	 mixture	 of	
water/ethanol	 (3/1	 v/v),	GNFs	were	 then	 immersed	 in	 the	 precursor	 solutions	 and	mixed	
under	ultrasonic	agitation	to	ensure	efficient	mixing,	followed	by	evaporation	of	the	solvent	
to	enhance	the	extent	of	adsorption	of	the	precursor	on	the		surfaces	of	GNFs.	The	GNFs	and	
metal	complex	were	then	heated	 in	air	and	finally	 in	an	 inert	atmosphere	to	promote	the	
efficient	decomposition	of	Fe(acac)3	to	Fe3O4.	
Confirmation	of	the	chemical	composition	and	structure	of	the	resultant	nanoparticles	in	the	
hybrid	structures	was	afforded	by	energy	dispersive	X-ray	 (EDX)	analysis	 (Figure	2a),	X-ray	
diffraction	 (XRD)	 (Figure	 2b),	 Raman	 spectroscopy	 (Figure	 2c)	 and	 high	 resolution	
transmission	electron	microscopy	(HRTEM)	(Figure	2d).		
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Figure	2.	(a)	A	representative	EDX	spectrum	of	the	Fe3O4NP/GNF	hybrids.	The	peaks	at	0.71,	6.40	and	
7.06	keV	correspond	to	Lα,	Kα	and	Kβ	fluorescence	peaks	of	Fe	respectively.	The	Kα	X-rays	of	O	are	
observed	at	0.53	keV.	The	atomic	ratio	of	Fe:O	of	3.0:4.2	matches	well	with	that	expected	for	Fe3O4,	
with	the	slight	excess	of	oxygen	attributed	to	a	small	degree	of	surface	functionality	of	the	GNF.	The	
large	peak	at	0.28	keV	is	due	to	the	Kα	X-rays	of	C	in	GNF.	The	large	fluorescence	peaks	near	8.00	and	
8.84	keV	are	the	Kα	and	Kβ	X-ray	fluorescence	signatures	of	Cu	respectively	(an	artefact	induced	from	
either	the	TEM	grid	mesh	or	the	instrument	column	assembly).	(b)	A	representative	XRD	pattern	for	
Fe3O4NP/GNF	hybrids	showing	the	indexed	crystal	planes	of	both	Fe3O4	and	GNF.	(c)	A	representative	
Raman	spectrum	of	the	Fe3O4-GNF	composite	showing	bands	associated	with	iron	oxide	(the	peaks	at	
209,	273,	386	and	577	cm-1	corresponding	to	one	A1g	and	three	Eg	modes	 in	haematite,	α-Fe2O3,	a	
known	by-product	of	the	heated-induced	transformation	of	Fe3O4	under	the	laser	irradiation	required	
for	Raman	spectroscopy	analysis)33	and	GNF	(1341,	1562	and	2684	cm-1	corresponding	to	D,	G	and	2D	
modes	 in	 graphitic	 carbon	 structures	 respectively).34	 (d)	 A	 representative	 TEM	 micrograph	 of	
magnetite	 nanoparticles	 on	 the	 external	 GNF	 surface.	 An	 interplanar	 spacing	 of	 0.25	 nm	 can	 be	
observed	that	is	consistent	with	the	(311)	Fe3O4	crystal	plane.	
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Comparative	TEM	analysis	revealed	magnetite	nanoparticles	on	GNF	with	average	sizes	of	11	
±	4	and	14	±	3	nm	for	the	materials	prepared	with	the	same	mass	ratio	of	Fe(acac)3:GNF	in	
water	and	water/ethanol	respectively	(Figure	3).		
	
	
Figure	3.	HR-TEM	micrographs	of	Fe3O4NP/GNF	prepared	using	the	same	ratio	of	 iron	precursor	to	
GNF	(Fe(acac)3:GNF,	1:1)	but	using	different	solvent	systems:	(a)	sample	Fe3O4NP/GNF-1:1w,	where	
dNP	=	11	±	4	nm;	(b)	sample	Fe3O4NP/GNF-1:1ew	where	dNP	=	14	±	3	nm.	The	corresponding	particle	
size	distributions	are	displayed	in	(c)	and	(d)	respectively.	
	
Analysis	 of	 multiple	 micrographs	 revealed	 that	 a	 greater	 proportion	 of	 the	 Fe3O4	
nanoparticles	 formed	 by	 the	 water/ethanol	 method	 appeared	 to	 reside	 on	 the	 external	
surface	of	the	GNFs	in	comparison	to	the	water	method,	where	the	number	of	nanoparticles	
confined	within	the	inner	channel	was	higher.	Since	the	surfaces	of	GNFs	are	hydrophobic,	
water/ethanol	wets	 the	GNFs	more	effectively	 than	pure	water,	allowing	 for	a	more	even	
distribution	of	magnetite.	The	poor	solubility	of	Fe(acac)3	in	water,	in	conjunction	with	the	
hydrophobic	properties	of	the	GNFs,	permitted	a	more	efficient	insertion	and	deposition	of	
the	precursor	molecules	into	the	internal	channel	of	the	GNFs.		
More	importantly,	magnetic	measurements	in	a	3	T	field	(Figure	5)	demonstrated	that	the	
Fe3O4NP/GNF	hybrid	material	prepared	using	the	same	mass	ratio	of	iron	precursor	to	GNF	
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(Fe(acac)3:GNF,	1:1)	if	made	in	water	possesses	a	significantly	lower	magnetisation	(Ms	=	51	
and	94	emu/g	 respectively)	 and	a	 comparable	 coercivity	 (Hc	 =	64	and	31	Oe	 respectively)	
relative	to	Fe3O4NP/GNF	prepared	using	water/ethanol	(Table	1).	The	observed	differences	
in	magnetic	behaviour	can	be	readily	explained	by	the	distinct	structural	properties	of	the	
hybrid	materials.	 In	Fe3O4NP/GNF-1:1w,	 the	mean	diameter	of	nanoparticles	 is	11	±	4	nm	
(above	the	critical	diameter	for	magnetite	to	exist	 in	a	superparamagnetic	state	of	dsp	≲	9	
nm)35	and	the	density	of	the	nanoparticles	on	GNF	is	low	(only	140	per	1	µm	of	GNF	length).	
Consequently,	 there	 are	 only	 weak	 magnetostatic	 interactions	 between	 neighbouring	
nanoparticles,	with	approximately	50%	of	the	nanoparticles	existing	in	a	superparamagnetic	
state	even	in	the	3	T	field	as	evident	from	the	measured	magnetisation	which,	therefore,	do	
not	contribute	to	the	total	magnetisation	of	the	hybrid	material.	
As	a	consequence,	water	was	used	to	prepare	a	series	of	samples	to	explore	the	effects	of	the	
ratio	of	the	magnetite	precursor	to	GNFs.	Using	different	starting	ratios	of	Fe(acac)3	to	GNFs	
allows	for	the	control	of	not	only	the	size	and	shape	of	Fe3O4	nanoparticle,	but	also	potentially	
their	 distribution	 along	 the	 GNF	 and	 relative	 positions	 with	 respect	 to	 each	 other.	More	
widely	distributed	and	slightly	larger	nanoparticles	are	expected	to	have	a	larger	surface	of	
interaction	with	surrounding	water	molecules	in	MRI	experiments,	which	should	yield	better	
contrast.	 We	 investigated	 three	 different	 mass	 ratios	 of	 Fe(acac)3:GNF,	 1:2,	 1:1	 and	 2:1,	
showing	that	the	average	nanoparticle	size	varies	from	8	to	14	nm	across	the	series	(Figure	
4).	
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Figure	 4.	 HR-TEM	 micrographs	 of	 Fe3O4NP/GNF	 prepared	 using	 three	 different	 mass	 ratios	 of	
Fe(acac)3:GNF:	(a)	Fe3O4NP/GNF-2:1w,	where	dNP	=	8	±	1	nm;	(b)	Fe3O4NP/GNF-1:1w,	where	dNP	=	11	
±	 4	 nm	 and	 (c)	 Fe3O4NP/GNF-1:2w,	 where	 dNP	 =	 14	 ±	 3	 nm,	 using	 water	 as	 the	 solvent.	 The	
corresponding	particle	size	distributions	are	displayed	in	(d),	(e)	and	(f)	respectively.	
	
There	 is	 a	 clear	 relationship	 between	 the	 average	 nanoparticle	 size	 and	 the	 ratio	 of	
Fe(acac)3:GNF.	We	observe	that	the	higher	the	ratio	of	the	precursor,	i.e.	a	greater	number	
of	nucleation	centres	on	GNFs,	leads	to	a	larger	number	of	particles	with	a	smaller	average	
size	and,	therefore,	a	narrower	particle	size	distribution	(Table	1).		
	
Table	1.	Conditions	used	for	the	synthesis	and	the	resultant	properties	of	the	Fe3O4NP/GNF	hybrid	
materials.	
Material	 Fe(acac)3:	
GNF	(w:w)	
Solvent	 dNP	/	
nm	
Density	/		
NP	µm-1	
Magnetic	
moment	/	emu	
g-1			
Coercivity,	
Oe	
Fe3O4NP/GNF-1:2w	 1:2	 water	 14	±	3	 310	 99	 173	
Fe3O4NP/GNF-1:1w	 1:1	 water	 11	±	4	 140	 51	 64	
Fe3O4NP/GNF-2:1w	 2:1	 water	 8	±	1	 >1000	 83	 82	
Fe3O4NP/GNF-1:1ew	 1:1	 ethanol	/	
water	
14	±	3	 370	 94	 51	
	
Most	significantly,	Fe3O4NP/GNF	prepared	in	a	1:2	mass	ratio	has	nanoparticles	that	are	well	
dispersed	 (Figure	4c)	due	 to	 the	 large	surface	of	 the	GNF.	Furthermore,	evaluation	of	 the	
magnetic	 properties	 of	 these	 materials	 yielded	 key	 insight	 into	 the	 structure-property	
relationships	of	nanoscale	magnetic	materials.	 For	example,	 Fe3O4NP/GNF-2:1w	possesses	
nanoparticles	 of	 a	mean	diameter	which	 is	 comparable	 or	 below	 the	 critical	 diameter	 dsp	
required	for	the	transition	of	magnetite	to	the	superparamagnetic	state	and	can	thus	explain	
the	high	magnetisation	of	this	material.	Furthermore,	a	high	density	of	nanoparticles	on	the	
surface	of	GNF	in	this	material	(>1000	per	1	µm	of	GNF	length)	provides	strong	magnetostatic	
interactions	 between	 them,	 which	 can	 be	 further	 enhanced	 by	 very	 effective	 dispersion	
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interactions	 between	 Fe3O4NP	 and	 GNF	 leading	 to	 an	 increase	 of	 the	 surface	 magnetic	
anisotropy	 parameter.	 All	 these	 phenomena	 can	 lead	 to	 an	 increase	 of	 the	 magnetic	
anisotropy	constant	and	‘freezing’	of	the	magnetic	moments	of	many	nanoparticles	 in	this	
material	(the	estimated	volume	fraction	of	nanoparticles	existing	in	the	superparamagnetic	
state	is	below	10%).	Overall,	both	the	magnetization	and	the	coercive	force	of	Fe3O4NP/GNF-
2:1w	 are	 enhanced	 as	 a	 result.	 Conversely,	 Fe3O4NP/GNF-1:2w	 possess	 relatively	 large	
nanoparticles,	with	a	comparatively	 lower	density	of	nanoparticles	on	 the	surface	of	GNF,	
leading	to	weaker	magnetostatic	interactions	and	thus	more	attractive	magnetic	properties	
(Figure	5).	
	
	
Figure	 5.	Magnetic	 properties	 of	 Fe3O4NP/GNF	 hybrids	 with	 varying	 ratios	 of	 Fe(acac)3:GNF	 and	
solvent	systems	(w	–	water,	ew	–	ethanol/water).	
	
Since	the	hybrid	Fe3O4NP/GNF	material,	prepared	in	water	using	a	1:2	ratio	of	Fe(acac)3:GNF,	
possesses	the	most	optimum	structure	and	magnetic	properties,	it	was	tested	as	a	contrast	
agent	 for	 MRI.	 However,	 in	 order	 to	 stabilise	 Fe3O4NP/GNF	 in	 water,	 a	 fundamental	
requirement	for	biological	applications,	Pluronic	F-127	was	added	to	the	composite	material,	
with	the	extent	of	coating	confirmed	with	thermogravimetric	analysis	to	be	11	%	by	mass.	
12	
	
The	efficiency	of	MRI	contrast	agents	depends	on	their	longitudinal	(r1)	and	transverse	(r2)	
relaxivities,	as	well	as	on	their	ratio.	The	efficiency	of	a	T2	contrast	agent	is	optimal	when	r2/r1	
ratio	 is	 the	 highest.	 To	 determine	 the	 r2/r1	 ratio	 in	 the	 presence	 of	 Fe3O4NP/GNF,	 the	
transverse	 relaxation	 (T2)	 and	 longitudinal	 relaxation	 (T1)	 of	 water	 protons	 in	 aqueous	
solutions	of	solubilised	Fe3O4NP/GNF	were	studied	for	a	range	of	concentrations	of	the	added	
contrast	agent.	T1	and	T2	weighted	images	were	obtained	as	described	in	the	Experimental	
section	and	T2	and	T1	relaxation	maps	derived	from	the	resulting	images	(Figure	6a	and	c).	
The	 inset	 in	 Figure	 6	 lists	 the	 Fe	 cation	 concentrations	 in	 five	 aqueous	 samples	 of	
Fe3O4NP/GNF	that	were	used	as	an	imaging	phantom.		
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	Figure	6.	Longitudinal	(r1)	and	transverse	(r2)	relaxivity	of	water	 in	the	presence	of	Fe3O4NP/GNF-
1:2w:Pluronic	F-127	at	9.4T:	(a)	-	(b)	saturation	recovery	images	of	water	phantoms	containing	five	
different	 concentrations	 of	 Fe3O4NP/GNF-1:2w:Pluronic	 F-127	 at	 two	 recovery	 delay	 times.	 Please	
note	that	the	recovery	at	10s	is	independent	of	the	Fe	ion	content	in	each	tube.		The	Fe	ion	content	in	
each	tube	is	shown	in	the	inset;	(c)	T1	relaxation	map	demonstrating	the	limited	dependence	of	the	
longitudinal	 relaxation	 on	 the	 Fe	 ion	 content	 in	 phantoms;	 (d)	 -	 (e)	 spin	 echo	 images	 of	 water	
phantoms	with	the	same	Fe	ion	content	as	in	(a)	-	(c);	(f)	corresponding	T2	map	obtained	using	T2	data	
analysis	 in	 each	 sample	 tube	 as	 described	 in	 the	 Experimental	 section.	 The	 following	 transverse	
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relaxation	time	constants	are	obtained	after:	(1)	red	-	(0.239	±	0.17)	s;	(2)	yellow	-	(0.185	±	0.010)	s;	
(3)	light	green	-	(0.137	±	0.010)	s;	(4)	light	blue	-	(0.108	±	0.090)	s;	(5)	dark	blue	-	(0.072	±		0.010)	s;	(g)	
transverse	 (red)	and	 longitudinal	 (blue)	 relaxation	rates	as	a	 function	of	 iron	content	 in	 the	added	
contrast	agent.	Relaxivity	is	the	slope	extracted	from	linear	fitting	of	the	data;	(h)	comparison	of	r2/r1	
ratio	for	commercial	Combidex	(C-dex),	Feridex	(F-dex),	Resovist	(R-vist)36	and	novel	NP	based	contrast	
MRI	agents37	relative	to	this	work	at	different	magnetic	field	strengths.			
	
The	influence	of	the	added	contrast	agent	on	the	transverse	proton	relaxation	is	highlighted	
in	 Figure	 6a.	 It	 is	 apparent	 that	 T2	 decreases	 with	 a	 corresponding	 increase	 of	 the	 iron	
concentration	in	the	added	contrast	agent.	On	the	contrary,	the	T1	map	displayed	in	Figure	6c	
shows	mediocre	dependence	of	the	longitudinal	relaxation	on	the	iron	content	for	the	same	
range	of	concentration	of	the	added	contrast	agent.	To	determine	r1	and	r2	relaxivities	we	
analysed	 the	 dependence	 of	 the	 relaxation	 rates	 r1	 (=1/T1)	 and	 r2	 (=1/T2)	 on	 the	 iron	 ion	
concentration	 in	 the	 added	 contrast	 agent	 (Figure	 6g).	 The	 relaxivities	 r1	 and	 r2	 were	
determined	by	linear	fitting	the	data	displayed	in	Figure	6g	and	resulted	in		r1	=	(0.7	±	0.3)	
mM/s	and		r2	=	(268	±	13)	mM/s.	The	determined	r2/r1	ratio	is	380	±	26	demonstrates	that	
aqueous	Fe3O4NP/GNF-1:2w:Pluronic	F-127	surpasses	the	best	commercially	available	agent	
(Resovist)	by	at	least	a	factor	of	6.	This	ratio	is	also	higher	(380	vs	306)	than	that	reported	for	
state-of-the-art	 magnetic	 nanoscale	 platforms37	 specifically	 designed	 for	 optimal	
performance	at	ultra-high	(9.4T)	magnetic	field.	This	value	highlights	the	great	potential	of	
Fe3O4NP/GNF	as	“smart”	contrast	agents	in	in	vivo	research	at	ultra-high	magnetic	fields	(7T	
and	higher)	as	the	majority	of	pre-clinical	scanners	operate	at	these	field	strengths.38		With	
the	 further	 development	 of	 “smart”	 theranostic	 agents,	 like	 the	 one	 proposed	 here,	 the	
potential	mechanism	for	personalised	nanomedicine		could	be	more	efficiently	explored	in	
the	 pre-clinical	 setting.40,41	 If	 successful,	 this	 could	 accelerate	 the	 pathway	 for	 bringing	
abdominal	theranostics	to	the	patient,	of	significant	benefit	due	to	the	ongoing,	worldwide	
rise	of	ultra-high	field	(7T)	clinical	MRI.42,43	
	
4. Conclusions	
In	conclusion,	we	have	developed	a	simple	one-step	procedure	to	assemble	Fe3O4NP/GNF	
hybrid	structures	from	widely	available	precursors.	The	influence	of	solvent,	and	the	ratio	of	
15	
	
starting	complex	to	GNF,	has	also	been	studied.	An	optimised	method	using	a	1:2	mass	ratio	
of	 Fe(III)	 acetylacetonate	 to	 GNF,	 prepared	 using	water	 as	 the	 solvent,	 showed	 excellent	
properties	 as	 an	MRI	 contrast	 agent,	 outperforming	 commercially	 available	materials	 and	
literature	 analogues.	Whilst	 the	 issue	 of	 biocompatibility	 of	 carbon	 nanotubes	 and	 their	
composites	 with	 magnetite	 nanoparticles	 still	 needs	 further	 assessment,44-48	 current	
literature	 studies	 suggest	 that	 analogous	 materials	 have	 limited	 toxicity	 to	 healthy	 and	
malignant	cells	and	can	be	injected	at	a	concentration	of	2.5	mg	of	iron	per	kg	of	body	weight	
without	any	apparent	harm	to	health.49,50	Furthermore,	the	recent	application	of	magnetic	
materials	 in	 CNTs	 for	 cell	 shepherding	 and	 magnetic	 fluid	 hyperthermia	 treatment51	
represents	 a	 significant	 breakthrough	 for	 the	 safe	 use	 of	 these	 materials.	 Thus,	 when	
combined	with	the	open	internal	channel	of	GNFs,	accessible	for	therapeutic	pharmaceutical	
agent	loading	alongside	the	Fe3O4	nanoparticles,	such	hybrid	nanostructures	can	offer	a	novel	
mechanism	for	magnetically-induced	drug	release,	in	addition	to	the	functional	MRI	contrast	
properties,	consequently	resulting	in	a	potentially	indispensable	contribution	to	the	emerging	
area	of	theranostics.	
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